JP7784120B2 - 幹細胞遊走剤を使用した糖尿病治療 - Google Patents

幹細胞遊走剤を使用した糖尿病治療

Info

Publication number
JP7784120B2
JP7784120B2 JP2021552459A JP2021552459A JP7784120B2 JP 7784120 B2 JP7784120 B2 JP 7784120B2 JP 2021552459 A JP2021552459 A JP 2021552459A JP 2021552459 A JP2021552459 A JP 2021552459A JP 7784120 B2 JP7784120 B2 JP 7784120B2
Authority
JP
Japan
Prior art keywords
abnormal
cells
diabetes
stem cells
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552459A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021075536A5 (https=
JPWO2021075536A1 (https=
Inventor
秀人 小島
智也 寺島
美和子 樫
Original Assignee
株式会社バイオジップコード
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社バイオジップコード filed Critical 株式会社バイオジップコード
Publication of JPWO2021075536A1 publication Critical patent/JPWO2021075536A1/ja
Publication of JPWO2021075536A5 publication Critical patent/JPWO2021075536A5/ja
Priority to JP2023117134A priority Critical patent/JP2023139101A/ja
Application granted granted Critical
Publication of JP7784120B2 publication Critical patent/JP7784120B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
JP2021552459A 2019-10-18 2020-10-16 幹細胞遊走剤を使用した糖尿病治療 Active JP7784120B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023117134A JP2023139101A (ja) 2019-10-18 2023-07-18 幹細胞遊走剤を使用した糖尿病治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019191369 2019-10-18
JP2019191369 2019-10-18
PCT/JP2020/039045 WO2021075536A1 (ja) 2019-10-18 2020-10-16 幹細胞遊走剤を使用した糖尿病治療

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023117134A Division JP2023139101A (ja) 2019-10-18 2023-07-18 幹細胞遊走剤を使用した糖尿病治療

Publications (3)

Publication Number Publication Date
JPWO2021075536A1 JPWO2021075536A1 (https=) 2021-04-22
JPWO2021075536A5 JPWO2021075536A5 (https=) 2022-08-09
JP7784120B2 true JP7784120B2 (ja) 2025-12-11

Family

ID=75538075

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552459A Active JP7784120B2 (ja) 2019-10-18 2020-10-16 幹細胞遊走剤を使用した糖尿病治療
JP2023117134A Withdrawn JP2023139101A (ja) 2019-10-18 2023-07-18 幹細胞遊走剤を使用した糖尿病治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023117134A Withdrawn JP2023139101A (ja) 2019-10-18 2023-07-18 幹細胞遊走剤を使用した糖尿病治療

Country Status (7)

Country Link
US (1) US20220403032A1 (https=)
EP (1) EP4035680A4 (https=)
JP (2) JP7784120B2 (https=)
KR (1) KR20220103718A (https=)
CN (1) CN114828890A (https=)
AU (1) AU2020367414A1 (https=)
WO (1) WO2021075536A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230152099A (ko) * 2021-02-26 2023-11-02 가부시키가이샤 바이오지프코드 당뇨병 및 합병증의 신규 치료, 진단 및 검출을 위한 방법 및 제제
IL312393A (en) * 2021-10-29 2024-06-01 Biozipcode Inc A method or factor with an HDAC regulator, for the treatment of diabetes and complications
CN115671112A (zh) * 2022-07-29 2023-02-03 中南民族大学 阿法替尼在防治二型糖尿病中的新用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542197A (ja) 2006-07-06 2009-12-03 メルク セローノ ソシエテ アノニム Ｃｓｆ３ｒポリペプチド及びそれらの使用
JP2010508265A (ja) 2006-10-30 2010-03-18 ドン・ア・ファーム・カンパニー・リミテッド Ｇ−ｃｓｆを含有する、糖尿性末梢神経病予防および治療剤
JP2010538275A (ja) 2007-08-31 2010-12-09 マサチューセッツ インスティテュート オブ テクノロジー 自己免疫疾患の処置
JP2019509988A (ja) 2016-02-05 2019-04-11 ヤンセン バイオテツク，インコーポレーテツド １型糖尿病の処置又は予防のための抗ｔｎｆ抗体、組成物、方法及び使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671936A1 (en) * 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION
JP2015024960A (ja) * 2011-11-17 2015-02-05 公益財団法人東京都医学総合研究所 Ｃｘｃｒ４活性阻害ペプチド及びその用途
US9139649B2 (en) * 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
US20180228907A1 (en) * 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
WO2016201214A1 (en) * 2015-06-12 2016-12-15 Stc. Unm Human glut5 specific inhibitors and methods of treatment
JP7087631B2 (ja) 2018-04-25 2022-06-21 住友電気工業株式会社 光接続部品及び光接続部品の製造方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009542197A (ja) 2006-07-06 2009-12-03 メルク セローノ ソシエテ アノニム Ｃｓｆ３ｒポリペプチド及びそれらの使用
JP2010508265A (ja) 2006-10-30 2010-03-18 ドン・ア・ファーム・カンパニー・リミテッド Ｇ−ｃｓｆを含有する、糖尿性末梢神経病予防および治療剤
JP2010538275A (ja) 2007-08-31 2010-12-09 マサチューセッツ インスティテュート オブ テクノロジー 自己免疫疾患の処置
JP2019509988A (ja) 2016-02-05 2019-04-11 ヤンセン バイオテツク，インコーポレーテツド １型糖尿病の処置又は予防のための抗ｔｎｆ抗体、組成物、方法及び使用

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AN, J. et al., Trichostatin A increases BDNF protein expression by improving XBP-1s/ATF6/GRP78 axis in Schwann cell, Biomed Pharmacother, 2021年01月, 発行日, Vol. 133, Article No. 111062, pp. 1-14
BROOKS, M.B., Erlotinib and Gefitinib, Epidermal Growth Factor Receptor Kinase Inhibitors, May Treat Non-Cancer-Re, Oncologist, 2013年, 発行日, Vol. 18, pp. e3-e5
COSTA, D.B. et al., Improvement of Type 2 Diabetes in a Lung Cancer Patient Treated With Erlotinib, Diabetes Care, 2006年, 発行日, Vol. 29, No. 7, p.1711
ELGAMAL, D.A. et al., Ultrastructure characterization of pancreatic beta-cells is accompanied by modulatory effects of the, Mol Cell Endocrinol, 2020年, 発行日, Vol. 503, Article No. 110700, pp. 1-12
EL-SERAFI, A. et al., The potentiality of histone deacetylase inhibitors for diabetes and obesity, Histone Modification in Therapy, 2020年, 発行日, 1st Edition, Chapter 14, pp. 361-371
SHARMA, S. et al., Histone deacetylase inhibitors: Future therapeutics for insulin resistance and type 2 diabetes, Pharmacol Res, 2016年, 発行日, Vol. 113, pp. 320-326
TSUKAMOTO, K. et al., Administration of Monoclonal Antibodies against Vascular Cell Adhesion Molecule-1/Very Late Antigen-, Cell Immunol, 1995年, 発行日, Vol. 165, pp. 193-201
小島秀人, 外5名, 糖尿病性神経障害は神経細胞に細胞融合を仕掛ける造血幹細胞疾患である, 第18回日本再生医療学会総会 プログラム抄録, 2019年02月22日, 掲載日, p. 288
小島秀人，外5名, 糖尿病の過食には骨髄由来脳内ミクログリアの分化異常が関与する, 再生医療, 2016年, 発行日, Vol. 15, Suppl., p. 248
樫美和子，外2名, 糖尿病における骨髄幹細胞の分化異常と糖毒性メモリー, 再生医療, 2013年, 発行日, Vol. 12, Suppl., p. 155
樫美和子，外2名, 糖尿病における骨髄幹細胞の分化異常－ヒストンデアセチラーゼ遺伝子の発現異常について－, 再生医療, 2011年, 発行日, Vol. 10, Suppl., p. 208
樫美和子，外5名, 糖尿病性神経障害の完治に向けた新規治療標的の同定, 第18回日本再生医療学会総会 プログラム抄録, 2019年, 掲載日, p. 109

Also Published As

Publication number Publication date
EP4035680A4 (en) 2024-01-24
EP4035680A1 (en) 2022-08-03
CN114828890A (zh) 2022-07-29
JP2023139101A (ja) 2023-10-03
AU2020367414A1 (en) 2022-05-19
JPWO2021075536A1 (https=) 2021-04-22
US20220403032A1 (en) 2022-12-22
KR20220103718A (ko) 2022-07-22
WO2021075536A1 (ja) 2021-04-22

Similar Documents

Publication Publication Date Title
JP6254125B2 (ja) 蛋白尿腎疾患の病因における可溶性ｕＰＡＲの役割
Lucas et al. Inhibition of transforming growth factor-β signaling induces left ventricular dilation and dysfunction in the pressure-overloaded heart
JP2023139101A (ja) 幹細胞遊走剤を使用した糖尿病治療
US20130316337A1 (en) Methods of Diagnosing and Treating an Inflammatory Response
Bu et al. The GABAA receptor influences pressure overload-induced heart failure by modulating macrophages in mice
Xue et al. A novel peptide relieves endothelial cell dysfunction in preeclampsia by regulating the PI3K/mTOR/HIF1α pathway
US20240139129A1 (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
JP2015508155A (ja) 膵臓β細胞障害における可溶性ＭＡＮＦ
JP2025157483A (ja) 異常幹細胞を標的とする糖尿病治療
Huang et al. Cardiomyocyte-derived Galectin-9 induces macrophage M2 polarization via the TIM3 pathway to attenuate myocardial remodeling post-myocardial infarction
HK40073293A (en) Diabetes therapy targeting abnormal stem cells
HK40073547A (en) Therapy for diabetes using stem cell migration agent
HK40074315A (en) Therapy for diabetes using stem cell migration agent
HK40073790A (en) Diabetes therapy targeting abnormal stem cells
HK40105070A (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
EP4424327A1 (en) Method or agent with hdac regulator, for treatment of diabetes and complications
CN108660203A (zh) Cxcr2基因在心脏相关疾病中的用途
Wu et al. Dapagliflozin targets RORγt to improve myocardial ischemia-reperfusion injury-induced heart failure by regulating the CD4+ T cell/Th17 cell axis within cardiac tissue
US20230017266A1 (en) Cyclooxygenase-2 Inhibition for the Treatment of SAA-high Asthma
Shen et al. Aerobic exercise improves ventricular remodeling by promoting macrophages to phagocytose dying cardiomyocytes in heart failure model
CN121494954A (zh) 靶向slc22a6的多肽、抗体、组合物及其在治疗和诊断动脉粥样硬化中的应用
Schöder et al. Brown Adipose Tissue is Associated with Improved Cardiometabolic Health 1 and Regulates Blood Pressure 2
BA BEST ABSTRACTS SITZUNG

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220608

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220608

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20220620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230908

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20231006

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250312

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250822

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251121

R150 Certificate of patent or registration of utility model

Ref document number: 7784120

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150